Marinus Pharmaceuticals I... (MRNS)
Marinus Pharmaceuticals Statistics
Share Statistics
Marinus Pharmaceuticals has 55.22M shares outstanding. The number of shares has increased by 0.52% in one year.
| Shares Outstanding | 55.22M |
| Shares Change (YoY) | 0.52% |
| Shares Change (QoQ) | 0.06% |
| Owned by Institutions (%) | 72.28% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 61,426 |
| FTD / Avg. Volume | 3.39% |
Short Selling Information
The latest short interest is 2.18M, so 3.95% of the outstanding shares have been sold short.
| Short Interest | 2.18M |
| Short % of Shares Out | 3.95% |
| Short % of Float | 3.96% |
| Short Ratio (days to cover) | 1.44 |
Valuation Ratios
The PE ratio is -1.03 and the forward PE ratio is -2.62. Marinus Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -1.03 |
| Forward PE | -2.62 |
| PS Ratio | 4.72 |
| Forward PS | 0.3 |
| PB Ratio | 8.72 |
| P/FCF Ratio | -1.24 |
| PEG Ratio | 0 |
Enterprise Valuation
Marinus Pharmaceuticals has an Enterprise Value (EV) of 135.98M.
| EV / Sales | 4.39 |
| EV / EBITDA | -1.08 |
| EV / EBIT | -1.15 |
| EV / FCF | -1.15 |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 6.58.
| Current Ratio | 4.07 |
| Quick Ratio | 4.01 |
| Debt / Equity | 6.58 |
| Debt / EBITDA | -0.88 |
| Debt / FCF | -0.93 |
| Interest Coverage | -7.78 |
Financial Efficiency
Return on Equity is -843.45% and Return on Invested Capital is -89.82%.
| Return on Equity | -843.45% |
| Return on Assets | -82.74% |
| Return on Invested Capital | -89.82% |
| Revenue Per Employee | $187,812.12 |
| Profits Per Employee | $-857,000 |
| Employee Count | 165 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.8 |
Taxes
| Income Tax | -1.54M |
| Effective Tax Rate | 1.08% |
Stock Price Statistics
The stock price has increased by -61.81% in the last 52 weeks. The beta is 1.26, so Marinus Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | -61.81% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 70.4 |
| Average Volume (20 Days) | 1,810,773 |
Income Statement
In the last 12 months, Marinus Pharmaceuticals had revenue of 30.99M and earned -141.41M in profits. Earnings per share was -2.63.
| Revenue | 30.99M |
| Gross Profit | 29.05M |
| Operating Income | -131.49M |
| Net Income | -141.41M |
| EBITDA | -125.5M |
| EBIT | -126.05M |
| Earnings Per Share (EPS) | -2.63 |
Balance Sheet
The company has 120.57M in cash and 110.36M in debt, giving a net cash position of 10.21M.
| Cash & Cash Equivalents | 120.57M |
| Total Debt | 110.36M |
| Net Cash | 10.21M |
| Retained Earnings | -571.93M |
| Total Assets | 63.62M |
| Working Capital | 22.9M |
Cash Flow
In the last 12 months, operating cash flow was -118M and capital expenditures -119K, giving a free cash flow of -118.12M.
| Operating Cash Flow | -118M |
| Capital Expenditures | -119K |
| Free Cash Flow | -118.12M |
| FCF Per Share | -2.2 |
Margins
Gross margin is 93.76%, with operating and profit margins of -424.3% and -456.31%.
| Gross Margin | 93.76% |
| Operating Margin | -424.3% |
| Pretax Margin | -461.27% |
| Profit Margin | -456.31% |
| EBITDA Margin | -404.97% |
| EBIT Margin | -424.3% |
| FCF Margin | -381.17% |
Dividends & Yields
MRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -96.73% |
| FCF Yield | -80.8% |
Analyst Forecast
The average price target for MRNS is $3, which is 445.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $3 |
| Price Target Difference | 445.5% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
Stock Splits
The last stock split was on Sep 23, 2020. It was a backward split with a ratio of 1:4.
| Last Split Date | Sep 23, 2020 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | -20.13 |
| Piotroski F-Score | 3 |